Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 22,160 | 25,130 | 31,634 | 35,442 | 26,793 |
| Other current assets | 216 | 268 | 75 | 145 | 214 |
| TOTAL | $22,376 | $25,398 | $31,709 | $35,587 | $27,007 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $22,376 | $25,398 | $31,709 | $35,587 | $27,007 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,814 | 11,142 | 13,181 | 11,512 | 10,133 |
| Accrued Expenses | 92 | 36 | 115 | 65 | 2 |
| TOTAL | $13,294 | $11,178 | $13,296 | $11,577 | $10,135 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 1,388 | N/A | N/A | N/A | N/A |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $13,294 | $11,178 | $13,296 | $11,577 | $10,135 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 32,582 | 26,526 | 26,492 | 25,615 | 25,457 |
| Retained earnings | -112,757 | -105,737 | -99,687 | -92,373 | -84,911 |
| TOTAL | $9,082 | $14,220 | $18,413 | $24,010 | $16,872 |
| Total Liabilities And Equity | $22,376 | $25,398 | $31,709 | $35,587 | $27,007 |